A Randomized, Placebo-Controlled Clinical Trial of Recombinant Human Erythropoietin in the Anemia of Prematurity1

2015 ◽  
pp. 306-313 ◽  
Author(s):  
William C. Mentzer ◽  
Kevin M. Shannon ◽  
Robert I. Abels ◽  
Patricia Freeman ◽  
Nancy Newton ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Recombinant Human Erythropoietin ◽  
Controlled Clinical Trial ◽  
Human Erythropoietin

scholarly journals Erythropoietin in Acute Kidney Injury (EAKI): a Pragmatic Randomized Clinical Trial

2022 ◽  
Author(s):  
Mabel Aoun ◽  
Ghassan Sleilaty ◽  
Celine Boueri ◽  
Eliane Younes ◽  
Kim Gabriel ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Acute Kidney Injury ◽  
Kidney Injury ◽  
Standard Of Care ◽  
Renal Recovery ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Human Erythropoietin ◽  
Significant Difference ◽  
Erythropoietin Treatment

Abstract Background Treatment with erythropoietin is well established for anemia in chronic kidney disease patients but not well studied in acute kidney injury.MethodsThis is a multicenter, randomized, pragmatic controlled clinical trial. It included 134 hospitalized patients with anemia defined as hemoglobin <11 g/dL and acute kidney injury defined as an increase of serum creatinine of 0.3 mg/dL within 48 hours or 1.5 times baseline. One arm received recombinant human erythropoietin 4000 UI subcutaneously every other day (intervention; n=67) and the second received standard of care (control; n=67) during the hospitalization until discharge or death. The primary outcome was the need for transfusion; secondary outcomes were death, renal recovery, need for dialysis.ResultsThere was no statistically significant difference in transfusion need (RR=1.05, 95%CI 0.65,1.68; p=0.855), in renal recovery full or partial (RR=0.96, 95%CI 0.81,1.15; p=0.671), in need for dialysis (RR=11.00, 95%CI 0.62, 195.08; p=0.102) or in death (RR=1.43, 95%CI 0.58,3.53; p=0.440) between the erythropoietin and the control group. ConclusionsErythropoietin treatment had no impact on transfusions, renal recovery or mortality in acute kidney injury patients with anemia. The trial was registered on ClinicalTrials.gov (NCT03401710, 17/01/2018).

scholarly journals Clinical effectiveness of 3 days preoperative treatment with recombinant human erythropoietin in total knee arthroplasty surgery: a clinical trial

QJM ◽  
2019 ◽  
Vol 113 (4) ◽  
pp. 245-252
Author(s):  
S -L Cao ◽  
Y Ren ◽  
Z Li ◽  
J Lin ◽  
X -S Weng ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Total Knee Arthroplasty ◽  
Blood Loss ◽  
Knee Arthroplasty ◽  
Recombinant Human Erythropoietin ◽  
Iron Supplement ◽  
Human Erythropoietin ◽  
Group A ◽  
Total Knee ◽  
Group B

Abstract Aims The purpose of study is to evaluate the effect and complication of preoperative short-term daily recombinant human erythropoietin (rhEPO) treatment for blood-saving in patients undergoing unilateral primary total knee arthroplasty (TKA). Methods This three-arm randomized clinical trial compared three different rhEPO-based treatment protocols for unilateral primary TKA. Group A: application of daily doses of rhEPO combined with iron supplement starting 3 days before surgery; Group B: application of daily doses of rhEPO combined with iron supplement starting the day of surgery; Group C: iron supplement alone. Perioperative hemoglobin (Hb) level gaps, total perioperative blood loss, reticulocyte levels and treatment-related complications were studied. Results A total of 102 patients were included (35, 35 and 32 patients in Groups A, B and C, respectively). Total blood loss (TBL) in Groups A, B and C was 490.84, 806.76 and 924.21 ml, respectively. Patients in Group A had a significant lower TBL than Groups B and C (A vs. B: P = 0.010; A vs. C: P &lt; 0.001). There was no difference as for TBL between Groups B and C (P = 0.377). Group A patients had significant smaller Hb decline than Group C on the third and fifth postoperative day (P = 0.049, P = 0.037), as well as than Group B on the fifth postoperative day (P = 0.048). There was no difference as for Hb decline between Groups B and C. No difference was shown in levels of inflammatory biomarkers or blood-saving protocol-related complications among three groups. Conclusions Daily dose of rhEPO combined with iron supplement administered 3 days before TKA procedures could significantly decrease perioperative blood loss and improve postoperative Hb levels, without significantly elevating risks of complication, when compared with admission of rhEPO on the day of surgery and iron supplement alone. Preoperative daily rhEPO treatment could be a more effective blood-saving protocol in TKA procedures.

Sign in / Sign up

Export Citation Format

Share Document